Until more data are available, we reserve bisphosphonates for women with evidence of decreased bone mineral density who are at increased risk of fracture and for those on clinical trials.
Catherine H. Van Poznak, MD
Advertisement
Articles by Catherine H. Van Poznak, MD
Advertisement
Latest Updated Articles
- Sixty Is the New Forty-or Is It the Other Way Around?
Published: October 23rd 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
3
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
4
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
5
